Femara 2, 5 mg FC tablets
PDF Leaflet Revision Date: 05 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Adjuvant treatment of hormone receptor positive invasive early breast cancer in postmenopausal women.
Dosage (summary)
2.5 mg once daily for 5 years or until disease relapse.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; may cause fetal harm.
Key Drug Interactions
- Avoid co-administration with tamoxifen and other anti-oestrogens.
- Caution with strong CYP3A4 and CYP2A6 inhibitors.
Contraindications
- Hypersensitivity to letrozole or excipients.
- Premenopausal endocrine status.
- Severe hepatic impairment (Child-Pugh grade C).
- Severe renal impairment (creatinine clearance < 10 mL/min).
Common side effects
- Hot flushes
- Fatigue
- Nausea
- Arthralgia
- Hypercholesterolemia
Counselling Points
- Take orally with or without food.
- Discuss contraception if of childbearing potential.
- Monitor for signs of tendonitis.
Serious warnings
- Monitor for osteoporosis and bone fractures.
- Risk of tendon disorders.
Important Disclaimer
The Femara 2, 5 mg FC tablets professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
